IGC Pharma (IGC)
Develops an investigational oral THC-and-melatonin therapy for Alzheimer’s-dementia agitation.
Something off on this page? Send us feedback.
Develops an investigational oral THC-and-melatonin therapy for agitation associated with Alzheimer’s dementia, alongside preclinical compounds and AI/data platforms. The small commercial stream comes from white-label and wellness products, while drug commercialization depends on trial results, regulatory approval, and third-party manufacturing.
Develops IGC-AD1, an investigational oral THC-and-melatonin solution for agitation associated with Alzheimer’s dementia, while advancing preclinical TGR-63 and IGC-M3 and building the MINT-AD and AHA data platforms. The commercial stream consists of white-label services and wellness and lifestyle products rather than pharmaceutical sales, and the company reports a single Life Sciences segment.
Operates from Potomac, Maryland, with activities across the United States, Canada, Colombia, and India, combining internal clinical operations and data management with external sites, CROs, vendors, and regulatory consultants. It has no approved drug or in-house manufacturing following the Vancouver asset sale; any approved-product commercialization would require third-party manufacturing or strategic partners. IGC-AD1 and its regulatory path are the central near-term dependencies.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $354.0K · Total debt $1.1M · Total assets $9.5M · Shareholders' equity $6.1M
- Revenue
- $265.0K
- Operating income
- −$2.8M
- Net income
- −$2.9M
No dividends on record.
| Institutions | 5.02% | 5.19M shares | |
|---|---|---|---|
| 37 holders · as of Jun 30, 2026 | |||
| Other | 94.98% | 98.19M shares | |
| remainder | |||
103.38M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Geode Capital Management, LLCInstitution | 0.85% | 879,394 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.79% | 814,914 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 0.68% | 703,798 | as of Jun 30, 2026 |
Advisorshares Investments LLCInstitution | 0.66% | 678,480 | as of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 0.42% | 437,317 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Axsome Therapeutics
Approved non-antipsychotic rival in Alzheimer's agitation.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| IGC Pharma | $0.2827 | +3.18% | $27.4M | — | — | 24.4 | −19.2% |
| Axsome Therapeutics | $205.46 | −0.02% | $10.57B | — | 1,225.8 | 13.6 | +44.2% |
| Median | — | 1,225.8 | 13.6 | +44.2% |